Zhejiang Cancer Hospital clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 281 studies whose lead sponsor is Zhejiang Cancer Hospital. 116 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Zhejiang Cancer Hospital studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Where
- China
- 246
Focus areas
Conditions Zhejiang Cancer Hospital leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 281. Browse all 281 →
- Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT)RecruitingNCT07441720Phase 2
- Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant AscitesRecruitingNCT07855640
- An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung CancerNot yet recruitingNCT07849712Not applicable
- Platinum-Free Regimen in Nasopharyngeal CarcinomaNot yet recruitingNCT07794488Phase 2
- A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal CarcinomatosisNot yet recruitingNCT07784413Phase 2
- Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion StudyRecruitingNCT07602907Phase 2
- SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal CancerRecruitingNCT07162714Phase 2
- Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical CancerRecruitingNCT07702838Not applicable
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07691515Phase 3
- IBI343 Combined With Chemotherapy in Advanced Pancreatic CancerRecruitingNCT07692750Phase 1/2
- Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC TherapyNot yet recruitingNCT07689929
- Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical CancerNot yet recruitingNCT07673211
- Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological MalignanciesRecruitingNCT07670949Not applicable
- A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian CancerNot yet recruitingNCT07586449
- CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.RecruitingNCT07538635Phase 2
- Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaRecruitingNCT07554898Phase 2
- A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid TumorsRecruitingNCT07538648Phase 1
- A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast CancerRecruitingNCT07455188
- Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System LymphomaRecruitingNCT07416890Phase 2
- To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.RecruitingNCT06784921
- Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesNot yet recruitingNCT07343479Phase 2
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingNCT07330544Phase 2
- Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric CancerRecruitingNCT07325630Phase 2
- Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard TherapyRecruitingNCT07284836Phase 2
- Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line TreatmentRecruitingNCT07285941Phase 2
- Real-Time Dynamic Imaging Study of Normal Pharyngolaryngeal Structures During Barium Swallow (GLAM-III)RecruitingNCT07264322
- LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy IndividualsRecruitingNCT07252362Not applicable
- An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II)RecruitingNCT07196696Not applicable
- Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic CancerRecruitingNCT07235930Phase 3
- A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast CancerNot yet recruitingNCT07180914
- Study on Safety and Efficacy of UCB-MNCs for Radiation-induced Lung InjuryNot yet recruitingNCT07177456Early Phase 1
- Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation EnteritisNot yet recruitingNCT07175207Early Phase 1
- Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma(CRIS-2 Trial)RecruitingNCT06509568Phase 2
- Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal CancerNot yet recruitingNCT07074353Phase 3
- Clinical Evaluation of GRAPE Model for Gastric Cancer ScreeningRecruitingNCT07067983
- a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .Not yet recruitingNCT07035808Phase 2
- Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast CancerRecruitingNCT07014410Phase 2
- Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes MechanismsRecruitingNCT06078930
- Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06741020Phase 1/2
- Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06422858Phase 2
- Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular LymphomaNot yet recruitingNCT06918015Phase 2
- SH-LPS System in Preoperative Planning for Liver ResectionNot yet recruitingNCT06911086Phase 2/3
- Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal MetastasesNot yet recruitingNCT06861218Phase 2
- Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCLRecruitingNCT06832267Not applicable
- Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody (PPR) in Third or Later Line Therapy of DLBCLRecruitingNCT06832228Not applicable
- Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence FactorsRecruitingNCT05920863Phase 2
- GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of RecurrenceRecruitingNCT05557578Phase 2
- Combined Screening for Gastrointestinal TumorsRecruitingNCT06478030
- Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPCNot yet recruitingNCT06752382Phase 2
- Pharmacokinetic Study of Tranexamic AcidRecruitingNCT06728670Not applicable